When: Gross margin must improve above 26.7% AND FCF demonstrates margin recovery translating into cash (not just operating income)

Then: Full reassessment of position sizing

When: Liffe cocoa below $5,000/ton

Then: Re-validates bull thesis for potential adding

When: Liffe cocoa above $7,000/ton

Then: Strengthens bear case; avoid adding

REDUCE (25-35% trim in tranches, not the aggressive 50% target)

• Beta of 0.40 makes MDLZ a defensive compounder unsuitable for momentum-based selling; one failed resistance test at 64.99 with 20.2M share volume does not constitute institutional distribution
• Dividend yield of 3.22% is a growing dividend funded at 78% of free cash flow with multi-decade track record, not comparable to fixed 4.5% Treasury yield over a 5-year horizon
• Forward EPS recovery to 3.36 versus TTM of 1.64 creates margin expansion story; forward P/E of 18.65 times is fair for quality staples vs TTM P/E of 38 times on depressed base
• Net debt to EBITDA of 3.2x is elevated but not distressed; interest coverage at 6 times and Q1 2026 sequential margin improvement support normalization thesis
• Entry at 62.50 is midpoint of 59.88 to 64.99 range—selling here means missing any breakout above resistance; recommend trim closer to 64 to 65 zone
• Current stop at 59.88 (4.2% stop, approximately 1.75x ATR) is overly tight for a 0.40 beta name; recommend widening to 58.30 (July swing low)
• Recommend staged execution: one-third trim at close above 63.50 with volume confirmation, one-third at 64.50 to 64.99 re-test, skip remainder if no confirmation
• Capital redeployment options: short-duration Treasuries at 4.5% yield pending cleaner entry, or protective put overlay at 60 strike for September/December expiry (1-2% position value cost)

→ vs aggressive: Aggressive entry at 62.50 sells in the middle of the range rather than at resistance; MDLZ is a 0.40 beta defensive, not a momentum name to be traded on resistance failures

→ vs aggressive: 50 SMA sitting 5.7% above 200 SMA with 10 EMA at 62.53 and price above all three moving averages means technical structure is intact; breakdown requires close below 61.09 on rising volume

→ vs aggressive: TTM P/E of 38x reflects depressed earnings base; forward P/E of 18.65x and EPS recovery to 3.36 vs TTM of 1.64 supports valuation normalization thesis

→ vs aggressive: Interest coverage at 6 times and Q1 2026 sequential margin improvement contradict 'ticking time bomb' characterization; 3.2x leverage is elevated but manageable

→ vs aggressive: Capital redeployment into cash without plan has opportunity cost; 4.5% Treasury yield or protective put overlay are superior uses of freed capital

MODERATE REDUCTION: Trim 25-30% now at current levels, hold remainder with re-evaluation framework, hedge with options, park freed capital in Treasuries or cash

• Trim 25-30% of position now in the $59-$63 zone; not 50% which would be panic sizing for a 0.4 beta name
• Hold remaining 70-75% with defined re-evaluation triggers: reduce another 15-20% if stock breaks below $59.88 on volume; hold if it breaks above $64.99 on volume
• Hedge residual position with put spread or collar in the $55-$60 zone expiring after next earnings print, rather than using stop loss
• Park freed capital in short-duration Treasuries at 4.5% yield or cash; do not immediately redeploy into next trade
• Beta of 0.4 means this is not a momentum name and should not be traded as such
• Gross margin recovery is slow, rates competition is real, and balance sheet gap between capital returns and FCF is a genuine vulnerability
• The failed resistance test at $64.99 deserves weight but does not confirm a reversal; MACD is barely below signal by 1 basis point, RSI at 53, stock above all major moving averages with 50 SMA still 5.7% above 200 SMA
• Macro regime is hawkish but stable: inflation above 4.5% at only 12% probability, recession odds at 8%
• Aggressive analyst's full exit at $62.50 is a momentum trade dressed as risk management; conservative analyst's tranche structure has high probability of not executing as designed
• The catalysts on the bullish side are largely priced in at current levels; risk-reward for adding is poor
• Structural concerns include slow gross margin recovery, real rates competition, and genuine gap between capital returns and free cash flow

→ vs aggressive: The $64.99 institutional distribution thesis is technically fragile - a single high-volume close at resistance is a ceiling, not a confirmed reversal; MACD barely below signal by 1 basis point and RSI at 53 is not a confirmed breakdown setup

→ vs aggressive: The rates argument overreaches by treating 4.5% yield as permanent; macro regime is hawkish but stable, not hawkish and accelerating

→ vs aggressive: Wanting to immediately redeploy capital into the next idea without identifying what that idea is creates bad trades that follow good ones

→ vs conservative: The tranche structure at $63.50 and $64.50-$64.99 has high probability of not executing - if MDLZ breaks out, tranches don't fire and position isn't reduced; if it breaks down before reaching levels, same problem

→ vs conservative: Protective puts cost carry and on a 0.4 beta name with low implied vol, the premium is expensive insurance against a relatively low-probability downside scenario

→ vs conservative: Rotating into 4.5% Treasuries caps return and creates timing risk on re-entry; same forces pushing ten-year higher are not guaranteed to persist